We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC... Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. Show more
La Commission européenne accorde une autorisation de mise sur le marché au LIVMARLI pour le traitement de la PFIC chez les patients âgés de trois mois et plus. L’approbation fait suite à l’avis...
Die Europäische Kommission erteilt LIVMARLI die Marktzulassung für die Behandlung von PFIC bei Patienten ab einem Alter von drei Monaten. Die Zulassung erfolgt im Anschluss an ein positives...
European Commission grants LIVMARLI marketing authorization for treatment of PFIC in patients three months and older. Approval follows positive opinion from CHMP concluding LIVMARLI’s clinical...
Submission based on the positive Phase 3 RESTORE study Mirum holds orphan designation for chenodiol in CTX Potential to have first and only therapy indicated for CTX in the US Mirum...
- VANTAGE PBC interim analysis shows 3.8 point reduction from baseline and 2.3 point placebo-adjusted (p=0.0026) reduction in primary endpoint of pruritus - VISTAS PSC interim analysis exceeds...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase...
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that on June 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.48 | 4.29857682254 | 34.43 | 36.635 | 33.45 | 473590 | 34.11419033 | CS |
| 4 | 11.34 | 46.1538461538 | 24.57 | 36.635 | 24.53 | 1144810 | 31.89155266 | CS |
| 12 | 11.39 | 46.4518760196 | 24.52 | 36.635 | 23.14 | 673348 | 28.6925397 | CS |
| 26 | 7.46 | 26.2214411248 | 28.45 | 36.635 | 23.14 | 622254 | 27.86527054 | CS |
| 52 | 9.47 | 35.8169440242 | 26.44 | 36.635 | 23.14 | 606182 | 28.64585722 | CS |
| 156 | 20.3 | 130.044843049 | 15.61 | 36.635 | 12.82 | 398915 | 25.50599996 | CS |
| 260 | 22.91 | 176.230769231 | 13 | 36.635 | 6.5126 | 296272 | 24.07222636 | CS |
Ganz
1 year ago
historyperson
1 year ago
Ganz
1 year ago
Cosa
1 year ago
Ganz
2 years ago
ClayTrader
5 years ago
CyrusDaVirus
5 years ago
zc182
5 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
